Perioperative fast track program in intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery in advanced ovarian cancer

Eur J Surg Oncol. 2011 Jun;37(6):543-8. doi: 10.1016/j.ejso.2011.03.134. Epub 2011 Apr 13.

Abstract

Introduction: Diffuse peritoneal dissemination in advanced ovarian cancer can be treated using optimal effort surgery involving peritonectomy procedures and the administration of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC).

Objective: To report on our experience in the treatment of advanced ovarian cancer using peritonectomy procedures and HIPEC through the fast track program.

Patients and method: From September 2008 until May 2010, forty-six patients with primary advanced (stage III-C) or recurrent ovarian cancer have been included in the fast track protocol if they had optimal cytoreduction CC-0 or CC-1 accompanied by HIPEC and there had no more than one digestive anastomosis.

Results: The mean peritoneal cancer index (PCI) was 12.35 (3-21). The median operation time was 380 min (200-540). Optimal surgery CC-0 was achieved in 38 of the 46 patients and CC-1 in the remaining 8. Mean postoperative hospital stay was 6.94 ± 1.56 days (3-11). Major morbidity rates were 15.3%. Paralytic ileus was the most frequent of these. There was no mortality related to the procedure.

Conclusion: Surgery with peritonectomy procedures and HIPEC in advanced ovarian carcinoma is possible under fast track surgery programs in patients with low volume peritoneal carcinomatosis. Prospective and randomized studies are needed.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma / drug therapy
  • Carcinoma / secondary
  • Carcinoma / surgery
  • Carcinoma / therapy*
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Hyperthermia, Induced*
  • Intestines / surgery
  • Intraoperative Period
  • Lymph Node Excision
  • Middle Aged
  • Morbidity
  • Neoplasm Staging
  • Ovarian Neoplasms / drug therapy
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / surgery
  • Ovarian Neoplasms / therapy*
  • Ovariectomy / methods
  • Peritoneal Neoplasms / drug therapy
  • Peritoneal Neoplasms / secondary
  • Peritoneal Neoplasms / surgery
  • Peritoneal Neoplasms / therapy*
  • Postoperative Complications / epidemiology
  • Postoperative Complications / etiology
  • Splenectomy
  • Treatment Outcome